- Dabrafenib in the treatment of metastatic melanoma +12014 | Publication without faculty affiliation
- Czech patient with lung adenocarcinoma with the BRAF V600E mutation succesfully treated with dabrafenib plus trametinib2021 | Faculty of Medicine in Pilsen, Central Library of Charles University
- Dabrafenib: the New Inhibitor of Hyperactive B-RAF Kinase2012 | Third Faculty of Medicine
- Adjuvant therapy for melanoma in real world2023 | Faculty of Medicine in Hradec Králové
- Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy2022 | Faculty of Pharmacy in Hradec Králové
- Dabrafenib: využití v léčbě BRAF pozitivních metastazujících melanomů2014 | Publication without faculty affiliation
- The Role of BRAF/MEK Inhibition in Metastatic Malignant Melanoma - a Case Study2016 | Faculty of Medicine in Hradec Králové
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib2015 | Publication without faculty affiliation
- Komentář ke studii (Prediktivní faktory účinnosti léčby kombinací dabrafenibu a trametinibu u pacientů s maligním melanomem - poolovaná analýza randomizovaných studií)2017 | Publication without faculty affiliation
- Research Report University Hospital for clinical assessment BRF 115532Publication without faculty affiliation
- Trametinib2016 | First Faculty of Medicine
- Targeted treatment of metastatic melanoma in a drug-addicted patient with pre-existing hepatitis C2019 | Third Faculty of Medicine
- Profound clinical and radiological response to BRAF inhibition in a 2-month-old diencephalic child with hypothalamic/chiasmatic glioma2016 | Second Faculty of Medicine
- Kudy v léčbě metastatického maligního melanomu2016 | Publication without faculty affiliation
- Komentář ke studii2020 | First Faculty of Medicine
- Case report of a patient with metastatic melanoma treated with several lines of systemic treatment2021 | First Faculty of Medicine
- Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial2018 | First Faculty of Medicine
- Adjuvant therapy of malignant melanoma: general and practical experience2021 | Faculty of Medicine in Hradec Králové
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial2018 | First Faculty of Medicine
- Dual targeted therapy in patients with malignant melanoma2017 | Faculty of Medicine in Hradec Králové
- New treatment options for malignant melanoma2014 | Faculty of Medicine in Pilsen
- The Significance of BRAFV600E Mutation in Thyroid Cancer in Terms of Novel Targeted Therapies - Overview of Current Knowledge and Studies2018 | Faculty of Medicine in Hradec Králové
- Advances in the treatment of metastatic melanoma2013 | Publication without faculty affiliation
- Nová éra v adjuvantní léčbě pokročilého melanomu2019 | First Faculty of Medicine
- Pokračování v léčbě vemurafenibem i po progresi onemocnění2016 | Publication without faculty affiliation
- Progress in the treatment of cerebral metastases in advanced melanoma2018 | Publication without faculty affiliation
- Léčba melanomu kombinací přípravků Tafinlar a Mekinist2015 | First Faculty of Medicine
- Možnosti léčby metastazujícího melanomu v kazuistikách2017 | Publication without faculty affiliation
- Potential utilization of neopterin measurements in the assessment of pyrexia in metastatic melanoma treated with combined targeted therapy: a case report2020 | Faculty of Pharmacy in Hradec Králové
